mProX™ Human NTRK3 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NTRK3, a gene involved in tumorigenesis, has been found to have various applications in different types of tumors. In a case of high-grade sarcoma, dual STRN-NTRK2 gene fusions were identified, and the patient showed a good clinical response to larotrectinib therapy. Another study reported three cases of Spitz tumors with RAF1 fusions, suggesting that RAF1 fused melanocytic neoplasms can represent a subgroup of Spitz tumors. In secretory carcinoma of salivary glands, ETV6-NTRK3 gene fusion was found, highlighting the importance of accurate diagnosis for effective management and treatment decisions. In a series of bone tumors, various kinase fusions involving NTRK1, RET, NTRK3, and BRAF were identified, emphasizing the role of NTRK fusions in these tumors. Lastly, macrofollicular architecture in invasive encapsulated follicular variant of papillary thyroid carcinoma was found to be a pitfall in diagnosis, and ETV6-NTRK3 fusion was identified in one case, suggesting the potential for targeted therapy in these cases. Overall, NTRK3 fusions have shown promise in improving clinical outcomes and guiding treatment decisions in various types of tumors.